51,269 XNAS Volume
XNAS 24 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Jason Campagna A. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 17,951 | 17,951 | - | - | Stock Option (Right to Buy) | |
| Violette M. Shelia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 13,305 | 13,305 | - | - | Stock Option (Right to Buy) | |
| Mark Iwicki T. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 37,222 | 0 | - | - | Stock Option (Right to Buy) | |
| T. Mary Thistle | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| Laporte D. Kathleen | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 1,947 | 0 | - | - | Stock Option (Right to Buy) | |
| Jason A. Campagna | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 87,738 | 0 | - | - | Stock Option (Right to Buy) | |
| Shelia Violette M. | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 37,500 | 61,374 | - | 0 | Common Stock | |
| Campagna A. Jason | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 37,500 | 37,500 | - | 0 | Common Stock | |
| Tzianabos O. Arthur | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 25,674 | 0 | - | - | Stock Option (Right to Buy) | |
| Tzianabos O. Arthur | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 25,674 | 25,674 | - | - | Stock Option (Right to Buy) | |
| Laporte Kathleen D. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| Xu Diyong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Iwicki T. Mark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 7,615 | 7,615 | - | - | Stock Option (Right to Buy) | |
| Iwicki T. Mark | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 7,615 | 0 | - | - | Stock Option (Right to Buy) | |
| Jason Campagna A. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 70,687 | 70,687 | - | - | Stock Option (Right to Buy) | |
| Laporte D. Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 37,222 | 37,222 | - | - | Stock Option (Right to Buy) | |
| P. Jodie Morrison | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 16,901 | 0 | - | - | Stock Option (Right to Buy) | |
| Shelia Violette M. | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 32,891 | 32,891 | - | - | Stock Option (Right to Buy) | |
| Arthur Tzianabos O. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| Violette Shelia M. | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 32,891 | 0 | - | - | Stock Option (Right to Buy) | |
| P. Jodie Morrison | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 394,445 | 0 | - | - | Stock Option (Right to Buy) | |
| Jason Campagna A. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 87,738 | 87,738 | - | - | Stock Option (Right to Buy) | |
| Mark Iwicki T. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 25,534 | 0 | - | - | Stock Option (Right to Buy) | |
| P. Jodie Morrison | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 152,700 | 152,700 | - | - | Stock Option (Right to Buy) | |
| P. Morrison Jodie | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 394,445 | 394,445 | - | - | Stock Option (Right to Buy) | |
| Jodie Morrison P. | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 152,700 | 152,700 | - | - | Stock Option (Right to Buy) | |
| Mary Thistle T. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Violette M. Shelia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 56,413 | 56,413 | - | - | Stock Option (Right to Buy) | |
| M. Shelia Violette | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 17,506 | 17,506 | - | - | Stock Option (Right to Buy) | |
| Kathleen D. Laporte | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 5,431 | 0 | - | - | Stock Option (Right to Buy) | |
| Jodie P. Morrison | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 152,700 | 0 | - | - | Stock Option (Right to Buy) | |
| Violette M. Shelia | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 56,413 | 0 | - | - | Stock Option (Right to Buy) | |
| D. Kathleen Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 1,947 | 1,947 | - | - | Stock Option (Right to Buy) | |
| Jodie Morrison P. | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 132,000 | 132,000 | - | 0 | Common Stock | |
| Morrison P. Jodie | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 152,700 | 0 | - | - | Stock Option (Right to Buy) | |
| Laporte D. Kathleen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 5,431 | 5,431 | - | - | Stock Option (Right to Buy) | |
| T. Iwicki Mark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 25,534 | 25,534 | - | - | Stock Option (Right to Buy) | |
| Diyong Xu | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| A. Jason Campagna | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 70,687 | 0 | - | - | Stock Option (Right to Buy) | |
| P. Jodie Morrison | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 16,901 | 16,901 | - | - | Stock Option (Right to Buy) | |
| Shelia M. Violette | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 17,506 | 0 | - | - | Stock Option (Right to Buy) | |
| Campagna Jason A. | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 17,951 | 0 | - | - | Stock Option (Right to Buy) | |
| M. Shelia Violette | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 13,305 | 0 | - | - | Stock Option (Right to Buy) | |
| Isaac Manke | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| Manke Isaac | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| S. David Grayzel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 2,569 | 2,569 | - | - | Stock Option (Right to Buy) | |
| Grayzel S. David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 18,595 | - | - | Stock Option (Right to Buy) | |
| David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 18,595 | - | - | Stock Option (Right to Buy) | |
| S. Grayzel David | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 2,569 | 0 | - | - | Stock Option (Right to Buy) | |
| Isaac Manke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 19,008 | 19,008 | - | - | Stock Option (Right to Buy) | |
| Isaac Manke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 19,008 | 19,008 | - | - | Stock Option (Right to Buy) | |
| Isaac Manke | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 2,627 | 0 | - | - | Stock Option (Right to Buy) | |
| Isaac Manke | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 19,008 | 0 | - | - | Stock Option (Right to Buy) | |
| Grayzel S. David | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 0 | - | - | Stock Option (Right to Buy) | |
| Grayzel David S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Manke Isaac | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 2,627 | 2,627 | - | - | Stock Option (Right to Buy) | |
| Shelia Violette M. | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 6,000 | 32,891 | - | - | Stock Option (Right to Buy) | |
| Violette Shelia M. | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.12 per share. | 11 Oct 2024 | 4,574 | 17,874 | - | 3.1 | 14,271 | Common Stock |
| Violette Shelia M. | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.29 per share. | 11 Oct 2024 | 6,000 | 23,874 | - | 7.3 | 43,740 | Common Stock |
| Shelia M. Violette | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 213 | 0 | - | - | Stock Option (Right to Buy) | |
| M. Shelia Violette | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 4,361 | 0 | - | - | Stock Option (Right to Buy) | |
| Shelia M. Violette | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.12 per share. | 08 Oct 2024 | 13,300 | 13,300 | - | 3.1 | 41,496 | Common Stock |
| Shelia M. Violette | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 13,300 | 213 | - | - | Stock Option (Right to Buy) | |
| David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 2,569 | 2,569 | - | - | Stock Option (Right to Buy) | |
| Kathleen D. Laporte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 25,534 | 25,534 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Jodie P. Morrison | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 394,445 | 394,445 | - | - | Stock Option (Right to Buy) | |
| Mary T. Thistle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Jason A. Campagna | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 70,687 | 70,687 | - | - | Stock Option (Right to Buy) | |
| Isaac Manke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Shelia M. Violette | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 56,413 | 56,413 | - | - | Stock Option (Right to Buy) | |
| Diyong Xu | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 24.20 per share. | 25 Mar 2024 | 265 | 7,983 | - | 24.2 | 6,413 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 1,095 | 8,248 | - | - | Common Stock | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 1,095 | 0 | - | - | Restricted Stock Units | |
| Michaud Charles | See Remarks | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Jan 2024 | 1,708 | 11,598 (0%) | 0% | 0.6 | 975 | Common Stock |
| Paul Alloway | See Remarks | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Jan 2024 | 7,280 | 28,036 (0%) | 0% | 0.6 | 4,120 | Common Stock |
| Paul Alloway | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 4,420 | 0 | - | - | Restricted Stock Units | |
| Charles Michaud | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 2,640 | 13,306 (0%) | 0% | - | Common Stock | |
| Charles Michaud | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 544 | 9,610 (0%) | 0% | - | Common Stock | |
| Charles Michaud | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 1,056 | 1,088 | - | - | Restricted Stock Units | |
| Michaud Charles | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 2,640 | 5,360 | - | - | Restricted Stock Units | |
| Alloway Paul | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 4,420 | 21,126 (0%) | 0% | - | Common Stock | |
| Charles Michaud | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 1,056 | 10,666 (0%) | 0% | - | Common Stock | |
| Paul Alloway | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 5,280 | 26,406 (0%) | 0% | - | Common Stock | |
| Paul Alloway | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 8,910 | 18,090 | - | - | Restricted Stock Units | |
| Charles Michaud | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 544 | 0 | - | - | Restricted Stock Units | |
| Paul Alloway | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 5,280 | 5,440 | - | - | Restricted Stock Units | |
| Alloway Paul | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 8,910 | 35,316 (0%) | 0% | - | Common Stock | |
| Arthur Tzianabos O. | Director | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 01 Jan 2024 | 13,037 | 128,778 (0%) | 0% | 0.6 | 7,445 | Common Stock |
| O. Arthur Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 14,280 | 0 | - | - | Restricted Stock Units | |
| Tzianabos O. Arthur | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 19,140 | 141,815 (0%) | 0% | - | Common Stock | |
| Tzianabos O. Arthur | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 19,140 | 19,720 | - | - | Restricted Stock Units | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 14,280 | 122,675 (0%) | 0% | - | Common Stock | |
| Julie Jordan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 1,548 | 4,318 (0%) | 0% | 0 | Common Stock | |
| Julie Jordan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 4,644 | 0 | - | - | Restricted Stock Units | |
| Julie Jordan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 387 | 0 | - | - | Restricted Stock Units | |
| Julie Jordan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 1,548 | 0 | - | - | Restricted Stock Units | |
| Julie Jordan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 03 Aug 2023 | 1,308 | 7,496 (0%) | 0% | 1.4 | 1,818 | Common Stock |
| Julie Jordan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 4,644 | 8,804 (0%) | 0% | 0 | Common Stock | |
| Julie Jordan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 03 Aug 2023 | 109 | 4,160 (0%) | 0% | 1.4 | 152 | Common Stock |
| Julie Jordan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 387 | 4,269 (0%) | 0% | 0 | Common Stock | |
| Julie Jordan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 03 Aug 2023 | 436 | 3,882 (0%) | 0% | 1.4 | 606 | Common Stock |
| Julie Jordan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.31 per share. | 02 Aug 2023 | 99 | 2,770 (0%) | 0% | 1.3 | 130 | Common Stock |
| Julie Jordan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2023 | 350 | 0 | - | - | Restricted Stock Units | |
| Julie Jordan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2023 | 350 | 2,869 (0%) | 0% | 0 | Common Stock | |
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 23,000 | 23,000 | - | - | Option (Right to Buy) | |
| Steven Gillis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 23,000 | 23,000 | - | - | Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 23,000 | 23,000 | - | - | Option (Right to Buy) | |
| Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 23,000 | 23,000 | - | - | Option (Right to Buy) | |
| Mary T. Thistle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 23,000 | 23,000 | - | - | Option (Right to Buy) | |
| Alise S. Reicin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 23,000 | 23,000 | - | - | Option (Right to Buy) | |
| Paul Alloway | See Remarks | Sale of securities on an exchange or to another person at price $ 1.45 per share. | 02 Mar 2023 | 10,965 | 16,706 (0%) | 0% | 1.4 | 15,863 | Common Stock |
| W. Bradford Smith | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 36,000 | 36,000 | - | - | Restricted Stock Units | |
| W. Bradford Smith | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 213,000 | 213,000 | - | - | Employee Stock Option (Right to Buy) | |
| Albert Seymour | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 632,000 | 632,000 | - | - | Employee Stock Option (Right to Buy) | |
| Albert Seymour | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 105,000 | 105,000 | - | - | Restricted Stock Units | |
| Michael Blum | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 17,000 | 17,000 | - | - | Restricted Stock Units | |
| Michael Blum | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 104,000 | 104,000 | - | - | Employee Stock Option (Right to Buy) | |
| Paul Alloway | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 164,000 | 164,000 | - | - | Employee Stock Option (Right to Buy) | |
| Paul Alloway | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 27,000 | 27,000 | - | - | Restricted Stock Units | |
| W. Bradford Smith | See Remarks | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 09 Jan 2023 | 3,729 | 14,219 (0%) | 0% | 1.4 | 5,188 | Common Stock |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 09 Jan 2023 | 10,616 | 108,395 (0%) | 0% | 1.4 | 14,762 | Common Stock |
| W. Bradford Smith | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,930 | 17,948 (0%) | 0% | - | Common Stock | |
| W. Bradford Smith | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,930 | 14,070 | - | - | Restricted Stock Units | |
| W. Bradford Smith | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,600 | 6,800 | - | - | Restricted Stock Units | |
| W. Bradford Smith | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,600 | 11,018 (0%) | 0% | - | Common Stock | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 19,140 | 38,860 | - | - | Restricted Stock Units | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 13,860 | 99,871 (0%) | 0% | - | Common Stock | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 19,140 | 119,011 (0%) | 0% | - | Common Stock | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 13,860 | 14,280 | - | - | Restricted Stock Units | |
| Albert Seymour | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 4,290 | 139,856 (0%) | 0% | - | Common Stock | |
| Albert Seymour | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,930 | 14,070 | - | - | Restricted Stock Units | |
| Albert Seymour | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 4,290 | 4,420 | - | - | Restricted Stock Units | |
| Albert Seymour | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,930 | 146,786 (0%) | 0% | - | Common Stock | |
| Michael Blum | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 2,640 | 11,042 (0%) | 0% | - | Common Stock | |
| Michael Blum | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 4,950 | 10,050 | - | - | Restricted Stock Units | |
| Michael Blum | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 2,640 | 2,720 | - | - | Restricted Stock Units | |
| Michael Blum | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 4,950 | 15,992 (0%) | 0% | - | Common Stock | |
| Paul Alloway | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 4,290 | 4,420 | - | - | Restricted Stock Units | |
| Paul Alloway | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 4,290 | 17,913 (0%) | 0% | - | Common Stock | |
| Paul Alloway | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 5,280 | 23,193 (0%) | 0% | - | Common Stock | |
| Paul Alloway | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 5,280 | 10,720 | - | - | Restricted Stock Units | |
| Albert Seymour | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2022 | 14,000 | 14,000 | - | - | Restricted Stock Units | |
| Albert Seymour | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2022 | 23,000 | 23,000 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Steven Gillis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Richard J. Gregory | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Mary T. Thistle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Kush M. Parmar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Alise S. Reicin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Albert Seymour | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2022 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| W. Bradford Smith | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 126,000 | 126,000 | - | - | Employee Stock Option (Right to Buy) | |
| W. Bradford Smith | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 58,000 | 58,000 | - | - | Restricted Stock Units | |
| Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 350,000 | 350,000 | - | - | Employee Stock Option (Right to Buy) | |
| Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 128,000 | 128,000 | - | - | Employee Stock Option (Right to Buy) | |
| Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| Timothy P. Kelly | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 4,800 | 4,800 | - | - | Restricted Stock Units | |
| Timothy P. Kelly | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 28,200 | 28,200 | - | - | Employee Stock Option (Right to Buy) | |
| W. Bradford Smith | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 6,600 | 13,400 | - | - | Restricted Stock Units | |
| W. Bradford Smith | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 6,600 | 6,600 (0%) | 0% | - | Common Stock | |
| W. Bradford Smith | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 2,182 | 4,418 (0%) | 0% | 3.8 | 8,248 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 13,860 | 28,140 | - | - | Restricted Stock Units | |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 5,354 | 86,011 (0%) | 0% | 3.8 | 20,239 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 13,860 | 91,365 (0%) | 0% | - | Common Stock | |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 1,661 | 131,646 (0%) | 0% | 3.8 | 6,279 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 4,290 | 8,710 | - | - | Restricted Stock Units | |
| Albert Seymour | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 4,290 | 133,307 (0%) | 0% | - | Common Stock | |
| Timothy P. Kelly | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,630 | 7,370 | - | - | Restricted Stock Units | |
| Timothy P. Kelly | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 3,630 | 3,630 (0%) | 0% | - | Common Stock | |
| Timothy P. Kelly | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 1,406 | 2,224 (0%) | 0% | 3.8 | 5,315 | Common Stock |
| Gabriel Cohn | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 4,290 | 8,710 | - | - | Restricted Stock Units | |
| Gabriel Cohn | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 4,290 | 4,290 (0%) | 0% | - | Common Stock | |
| Gabriel Cohn | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 1,661 | 2,629 (0%) | 0% | 3.8 | 6,279 | Common Stock |
| Timothy P. Kelly | See Remarks. | Sale of securities on an exchange or to another person at price $ 7.70 per share. | 03 Sep 2021 | 54 | 0 (0%) | 0% | 7.7 | 416 | Common Stock |
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Steven Gillis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Richard J. Gregory | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Mary T. Thistle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Kush M. Parmar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Alise S. Reicin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Timothy P. Kelly | See Remarks | Sale of securities on an exchange or to another person at price $ 11.16 per share. | 01 Mar 2021 | 6,232 | 0 (0%) | 0% | 11.2 | 69,563 | Common Stock |
| W. Bradford Smith | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 05 Feb 2021 | 13,500 | 0 (0%) | 0% | 14.3 | 192,425 | Common Stock |
| W. Bradford Smith | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 13,500 | 101,904 | - | - | Employee Stock Option (Right to Buy) | |
| W. Bradford Smith | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| W. Bradford Smith | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 122,000 | 122,000 | - | - | Employee Stock Option (Right to Buy) | |
| W. Bradford Smith | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 05 Feb 2021 | 13,500 | 13,500 (0%) | 0% | 0.6 | 8,640 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 42,000 | 42,000 | - | - | Restricted Stock Units | |
| Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 254,000 | 254,000 | - | - | Employee Stock Option (Right to Buy) | |
| Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 13,000 | 13,000 | - | - | Restricted Stock Units | |
| Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 78,000 | 78,000 | - | - | Employee Stock Option (Right to Buy) | |
| Timothy P. Kelly | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 11,000 | 11,000 | - | - | Restricted Stock Units | |
| Timothy P. Kelly | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 65,000 | 65,000 | - | - | Employee Stock Option (Right to Buy) | |
| Gabriel Cohn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 13,000 | 13,000 | - | - | Restricted Stock Units | |
| Gabriel Cohn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 78,000 | 78,000 | - | - | Employee Stock Option (Right to Buy) | |
| Timothy P. Kelly | See Remarks | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 02 Feb 2021 | 500 | 0 (0%) | 0% | 13 | 6,500 | Common Stock |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.63 per share. | 02 Feb 2021 | 500 | 500 (0%) | 0% | 6.6 | 3,316 | Common Stock |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 500 | 44,500 | - | - | Employee Stock Options | |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.63 per share. | 01 Feb 2021 | 2,000 | 2,000 (0%) | 0% | 6.6 | 13,263 | Common Stock |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 2,000 | 34,001 | - | - | Employee Stock Options | |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 2,000 | 43,500 | - | - | Employee Stock Options | |
| Timothy P. Kelly | See Remarks | Sale of securities on an exchange or to another person at price $ 12.36 per share. | 01 Feb 2021 | 4,000 | 0 (0%) | 0% | 12.4 | 49,460 | Common Stock |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.89 per share. | 01 Feb 2021 | 2,000 | 4,000 (0%) | 0% | 2.9 | 5,789 | Common Stock |
| Timothy P. Kelly | See Remarks | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 12 Jan 2021 | 500 | 0 (0%) | 0% | 13 | 6,500 | Common Stock |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2021 | 500 | 45,000 | - | - | Employee Stock Options | |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.63 per share. | 12 Jan 2021 | 500 | 500 (0%) | 0% | 6.6 | 3,316 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 06 Jan 2021 | 9,897 | 134,120 (0%) | 0% | 12.1 | 119,395 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.05 per share. | 06 Jan 2021 | 5,103 | 129,017 (0%) | 0% | 12.0 | 61,469 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.44 per share. | 05 Jan 2021 | 10,000 | 144,017 (0%) | 0% | 11.4 | 114,422 | Common Stock |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.89 per share. | 04 Jan 2021 | 2,000 | 4,000 (0%) | 0% | 2.9 | 5,789 | Common Stock |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 2,000 | 36,001 | - | - | Employee Stock Options | |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 2,000 | 45,500 | - | - | Employee Stock Options | |
| Timothy P. Kelly | See Remarks | Sale of securities on an exchange or to another person at price $ 11.50 per share. | 04 Jan 2021 | 4,000 | 0 (0%) | 0% | 11.5 | 45,983 | Common Stock |
| Timothy P. Kelly | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.63 per share. | 04 Jan 2021 | 2,000 | 2,000 (0%) | 0% | 6.6 | 13,263 | Common Stock |
| Kush M. Parmar | Director | Sale of securities on an exchange or to another person at price $ 12.82 per share. | 22 Dec 2020 | 480,000 | 4,354,484 (9%) | 1% | 12.8 | 6,153,600 | Common Stock |
| Kush M. Parmar | Director | Sale of securities on an exchange or to another person at price $ 12.82 per share. | 22 Dec 2020 | 20,000 | 181,435 (0%) | 0% | 12.8 | 256,400 | Common Stock |
| Kush M. Parmar | Director | Sale of securities on an exchange or to another person at price $ 13.06 per share. | 14 Dec 2020 | 151,138 | 5,163,346 (11%) | 0% | 13.1 | 1,973,998 | Common Stock |
| Kush M. Parmar | Director | Sale of securities on an exchange or to another person at price $ 11.88 per share. | 14 Dec 2020 | 13,703 | 201,435 (0%) | 0% | 11.9 | 162,792 | Common Stock |
| Kush M. Parmar | Director | Sale of securities on an exchange or to another person at price $ 13.06 per share. | 14 Dec 2020 | 6,297 | 215,138 (0%) | 0% | 13.1 | 82,244 | Common Stock |
| Kush M. Parmar | Director | Sale of securities on an exchange or to another person at price $ 11.88 per share. | 14 Dec 2020 | 328,862 | 4,834,484 (10%) | 0% | 11.9 | 3,906,881 | Common Stock |
| Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2020 | 36,000 | 36,000 | - | - | Option (Right to Buy) | |
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Steven Gillis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Richard J. Gregory | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Mary T. Thistle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Kush M. Parmar | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Alise Reicin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Timothy P. Kelly | See Remarks | Sale of securities on an exchange or to another person at price $ 13.01 per share. | 17 Mar 2020 | 1,315 | 0 (0%) | 0% | 13.0 | 17,109 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2020 | 12,000 | 103,404 | - | - | Employee Stock Option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.63 per share. | 03 Feb 2020 | 12,000 | 12,000 (0%) | 0% | 0.6 | 7,579 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 16.16 per share. | 03 Feb 2020 | 12,000 | 0 (0%) | 0% | 16.2 | 193,866 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 16.16 per share. | 03 Feb 2020 | 12,500 | 77,505 (0%) | 0% | 16.2 | 202,021 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 15.45 per share. | 29 Jan 2020 | 8,857 | 509,970 (1%) | 0% | 15.4 | 136,808 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 15.45 per share. | 29 Jan 2020 | 509,970 | 0 (0%) | 1% | 15.5 | 7,879,037 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 15.51 per share. | 24 Jan 2020 | 65,891 | 518,827 (1%) | 0% | 15.5 | 1,021,936 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 15.77 per share. | 24 Jan 2020 | 193,359 | 584,718 (1%) | 0% | 15.8 | 3,049,600 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 15.69 per share. | 24 Jan 2020 | 380,256 | 778,077 (1%) | 0% | 15.7 | 5,965,000 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 20.50 per share. | 02 Jan 2020 | 6,000 | 0 (0%) | 0% | 20.5 | 122,984 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.63 per share. | 02 Jan 2020 | 6,000 | 6,000 (0%) | 0% | 0.6 | 3,790 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2020 | 6,000 | 115,404 | - | - | Employee Stock Option | |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.50 per share. | 02 Jan 2020 | 12,500 | 90,005 (0%) | 0% | 20.5 | 256,191 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.50 per share. | 02 Jan 2020 | 9,133 | 154,017 (0%) | 0% | 20.5 | 187,216 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 21.95 per share. | 24 Dec 2019 | 151,233 | 1,766,106 (4%) | 0% | 22.0 | 3,319,579 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 21.95 per share. | 24 Dec 2019 | 198,767 | 2,321,199 (5%) | 0% | 22.0 | 4,362,956 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 19 Dec 2019 | 11,999 | 2,594,350 (5%) | 0% | 21.5 | 257,981 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 21.68 per share. | 19 Dec 2019 | 7,168 | 2,606,349 (5%) | 0% | 21.7 | 155,371 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 21.68 per share. | 19 Dec 2019 | 5,454 | 1,983,064 (4%) | 0% | 21.7 | 118,219 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 21.83 per share. | 19 Dec 2019 | 56,595 | 1,917,339 (4%) | 0% | 21.8 | 1,235,435 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 21.83 per share. | 19 Dec 2019 | 74,384 | 2,519,966 (5%) | 0% | 21.8 | 1,623,758 | Common Stock |
| Flynn E James | Other, Possible Member of 10% Group | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 19 Dec 2019 | 9,130 | 1,973,934 (4%) | 0% | 21.5 | 196,297 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2019 | 111,000 | 111,000 | - | - | Employee Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2019 | 358,000 | 358,000 | - | - | Employee Stock Option (Right to Buy) | |
| Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2019 | 110,000 | 110,000 | - | - | Employee Stock Option (Right to Buy) | |
| Timothy P. Kelly | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2019 | 112,000 | 112,000 | - | - | Employee Stock Option (Right to Buy) | |
| Gabriel Cohn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2019 | 15,000 | 15,000 | - | - | Employee Stock Option (Right to Buy) | |
| Gabriel Cohn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2019 | 120,000 | 120,000 | - | - | Employee Stock Option (Right to Buy) | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 29 Nov 2019 | 6,000 | 0 (0%) | 0% | 16 | 96,000 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2019 | 6,000 | 121,404 | - | - | Employee Stock Option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2019 | 6,000 | 127,404 | - | - | Employee Stock Option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 16.21 per share. | 29 Nov 2019 | 6,000 | 0 (0%) | 0% | 16.2 | 97,266 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 29 Nov 2019 | 6,000 | 6,000 (0%) | 0% | 0.6 | 3,840 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 29 Nov 2019 | 6,000 | 6,000 (0%) | 0% | 0.6 | 3,840 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 16.25 per share. | 29 Nov 2019 | 12,500 | 102,505 (0%) | 0% | 16.3 | 203,176 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 16.04 per share. | 29 Nov 2019 | 12,500 | 115,005 (0%) | 0% | 16.0 | 200,559 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.06 per share. | 29 Nov 2019 | 9,300 | 172,450 (0%) | 0% | 16.1 | 149,390 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.23 per share. | 29 Nov 2019 | 9,300 | 163,150 (0%) | 0% | 16.2 | 150,970 | Common Stock |
| Richard J. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 18 Nov 2019 | 10,806 | 10,806 (0%) | 0% | 0.0 | 324 | COMMON STOCK |
| Richard J. Gregory | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2019 | 10,806 | 0 | - | - | Employee Stock Option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 17.38 per share. | 01 Oct 2019 | 5,900 | 100 (0%) | 0% | 17.4 | 102,544 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2019 | 6,000 | 133,404 | - | - | Employee Stock Option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 18.23 per share. | 01 Oct 2019 | 100 | 0 (0%) | 0% | 18.2 | 1,823 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 01 Oct 2019 | 6,000 | 6,000 (0%) | 0% | 0.6 | 3,840 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.23 per share. | 01 Oct 2019 | 100 | 127,505 (0%) | 0% | 18.2 | 1,823 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 17.39 per share. | 01 Oct 2019 | 12,400 | 127,605 (0%) | 0% | 17.4 | 215,645 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.38 per share. | 01 Oct 2019 | 9,200 | 181,850 (0%) | 0% | 17.4 | 159,936 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.23 per share. | 01 Oct 2019 | 100 | 181,750 (0%) | 0% | 18.2 | 1,823 | Common Stock |
| Timothy P. Kelly | See Remarks | Sale of securities on an exchange or to another person at price $ 19.94 per share. | 05 Sep 2019 | 1,166 | 0 (0%) | 0% | 19.9 | 23,251 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2019 | 6,000 | 139,404 | - | - | Employee Stock Option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 18.74 per share. | 03 Sep 2019 | 6,000 | 0 (0%) | 0% | 18.7 | 112,419 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 03 Sep 2019 | 6,000 | 6,000 (0%) | 0% | 0.6 | 3,840 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.75 per share. | 03 Sep 2019 | 12,500 | 140,005 (0%) | 0% | 18.7 | 234,320 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.74 per share. | 03 Sep 2019 | 9,300 | 191,050 (0%) | 0% | 18.7 | 174,284 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 01 Aug 2019 | 6,000 | 6,000 (0%) | 0% | 0.6 | 3,840 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2019 | 6,000 | 145,404 | - | - | Employee Stock Option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 17.37 per share. | 01 Aug 2019 | 6,000 | 0 (0%) | 0% | 17.4 | 104,191 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 17.37 per share. | 01 Aug 2019 | 12,500 | 152,505 (0%) | 0% | 17.4 | 217,111 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.37 per share. | 01 Aug 2019 | 9,300 | 200,350 (0%) | 0% | 17.4 | 161,523 | Common Stock |
| Alise S. Reicin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2019 | 31,160 | 31,160 | - | - | Option (Right to Buy) | |
| Siyamak Rasty | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 09 Jul 2019 | 8,000 | 222,707 (0%) | 0% | 20 | 160,000 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 01 Jul 2019 | 6,000 | 0 (0%) | 0% | 19.0 | 113,971 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 01 Jul 2019 | 6,000 | 6,000 (0%) | 0% | 0.6 | 3,840 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2019 | 6,000 | 151,404 | - | - | Employee Stock Option | |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.98 per share. | 01 Jul 2019 | 12,500 | 165,005 (0%) | 0% | 19.0 | 237,300 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.56 per share. | 01 Jul 2019 | 100 | 209,650 (0%) | 0% | 19.6 | 1,956 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.98 per share. | 01 Jul 2019 | 9,200 | 209,750 (0%) | 0% | 19.0 | 174,583 | Common Stock |
| Matthew R. Patterson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 15,580 | 15,580 | - | - | Option (Right to Buy) | |
| Steven Gillis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 15,580 | 15,580 | - | - | Option (Right to Buy) | |
| Flynn E James | Other, *Director by Deputization | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 15,580 | 15,580 | - | - | Stock Option (Right to Buy) | |
| Richard J. Gregory | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 15,580 | 15,580 | - | - | Option (Right to Buy) | |
| Mary T. Thistle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 15,580 | 15,580 | - | - | Option (Right to Buy) | |
| Kush M. Parmar | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 15,580 | 15,580 | - | - | Option (Right to Buy) | |
| Cameron Wheeler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 15,580 | 15,580 | - | - | Option (Right to Buy) | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Sale of securities on an exchange or to another person at price $ 19.94 per share. | 03 Jun 2019 | 6,000 | 0 (0%) | 0% | 19.9 | 119,664 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2019 | 6,000 | 157,404 | - | - | Employee Stock Option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 03 Jun 2019 | 6,000 | 6,000 (0%) | 0% | 0.6 | 3,840 | Common Stock |
| Arthur O. Tzianabos | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 19.86 per share. | 03 Jun 2019 | 12,500 | 177,505 (0%) | 0% | 19.9 | 248,263 | Common Stock |
| Siyamak Rasty | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 03 Jun 2019 | 8,000 | 230,707 (0%) | 0% | 20.2 | 161,778 | Common Stock |
| Albert Seymour | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.90 per share. | 03 Jun 2019 | 9,300 | 218,950 (0%) | 0% | 19.9 | 185,093 | Common Stock |
| Timothy P. Kelly | See Remarks | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 03 Jun 2019 | 1,288 | 0 (0%) | 0% | 20.0 | 25,765 | Common Stock |
| Kush M. Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 21.47 per share. | 16 May 2019 | 24,600 | 221,435 (0%) | 0% | 21.5 | 528,162 | Common Stock |
| Kush M. Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 21.47 per share. | 16 May 2019 | 590,400 | 5,314,484 (12%) | 1% | 21.5 | 12,675,888 | Common Stock |
| Flynn E James | Other, *Director by Deputization | Purchase of securities on an exchange or from another person at price $ 22.50 per share. | 12 Apr 2019 | 533,333 | 1,158,333 (2%) | 1% | 22.5 | 11,999,993 | Common Stock |
| W. Bradford Smith | CFO, Treasurer & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2018 | 88,000 | 88,000 | - | - | Employee stock option | |
| Arthur Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2018 | 203,000 | 203,000 | - | - | Employee stock option | |
| Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2018 | 74,000 | 74,000 | - | - | Employee stock option | |
| Timothy P. Kelly | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2018 | 66,000 | 66,000 | - | - | Employee stock option | |
| Kush Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 26.01 per share. | 10 Dec 2018 | 14,952 | 5,904,884 (15%) | 0% | 26.0 | 388,828 | Common Stock |
| Kush Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 10 Dec 2018 | 623 | 246,035 (0%) | 0% | 26.0 | 16,201 | Common Stock |
| Kush Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 23 Nov 2018 | 1,187 | 246,658 (0%) | 0% | 20.0 | 23,783 | Common Stock |
| Kush Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 23 Nov 2018 | 28,495 | 5,919,836 (15%) | 0% | 20.0 | 570,926 | Common Stock |
| Kush Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 16 Nov 2018 | 21,036 | 247,845 (0%) | 0% | 20.2 | 424,927 | Common Stock |
| Kush Parmar | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.20 per share. | 16 Nov 2018 | 504,864 | 5,948,331 (15%) | 1% | 20.2 | 10,198,253 | Common Stock |
| Mahendra Gopaldas Shah | None | Grant, award, or other acquisition of securities at price $ 16.00 per share. | 02 Apr 2018 | 250,000 | 909,742 (2%) | 0% | 16 | 4,000,000 | Common Stock |
| Steven Gillis | None | 02 Apr 2018 | 4,683,238 | 0 | - | - | Series A Preferred Stock | ||
| Steven Gillis | None | 02 Apr 2018 | 6,068,695 | 6,068,695 (16%) | 16% | 0 | Common Stock | ||
| Steven Gillis | None | 02 Apr 2018 | 1,385,457 | 0 | - | - | Series B Preferred Stock | ||
| Flynn E James | Other | 02 Apr 2018 | 669,034 | 669,034 (1%) | 1% | 0 | Common Stock | ||
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 02 Apr 2018 | 625,000 | 625,000 (1%) | 1% | 16 | 10,000,000 | Common Stock |
| Flynn E James | Other | 02 Apr 2018 | 1,319,484 | 1,988,518 (5%) | 3% | 0 | Common Stock | ||
| Flynn E James | Other | 02 Apr 2018 | 1,319,483 | 1,988,517 (5%) | 3% | 0 | Common Stock | ||
| Flynn E James | Other | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 02 Apr 2018 | 625,000 | 2,613,517 (7%) | 1% | 16 | 10,000,000 | Common Stock |
| Flynn E James | Other | 02 Apr 2018 | 6,944,444 | 0 | - | - | Series B Preferred Stock | ||
| Flynn E James | Other | 02 Apr 2018 | 6,944,445 | 0 | - | - | Series B Preferred Stock | ||
| Flynn E James | Other | 02 Apr 2018 | 3,521,126 | 0 | - | - | Series A Preferred Stock | ||
| Flynn E James | Other | 02 Apr 2018 | 3,521,126 | 0 | - | - | Series A Preferred Stock | ||
| Flynn E James | Other | 02 Apr 2018 | 669,034 | 669,034 (1%) | 1% | 0 | Common Stock | ||
| Kush Parmar | Director, Ten Percent Owner | 02 Apr 2018 | 5,392,037 | 6,722,076 (18%) | 14% | 0 | Common Stock | ||
| Matthew R. Patterson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 8,360 | 8,360 | - | - | Employee stock option | |
| Mahendra Gopaldas Shah | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 31,160 | 31,160 | - | - | Employee stock options | |
| Steven Gillis | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 31,160 | 31,160 | - | - | Employee stock option | |
| W. Bradford Smith | CFO, Treasurer & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 49,711 | 49,711 | - | - | Employee stock option | |
| Flynn E James | Other | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 31,160 | 31,160 | - | - | Stock Option (Right to Buy) | |
| Arthur Tzianabos | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 92,376 | 92,376 | - | - | Employee stock option | |
| Richard J. Gregory | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 31,160 | 31,160 | - | - | Employee stock option | |
| Mary T. Thistle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 31,160 | 31,160 | - | - | Employee stock option | |
| Kush Parmar | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 31,160 | 31,160 | - | - | Employee stock option | |
| Siyamak Rasty | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 30,780 | 30,780 | - | - | Employee stock option | |
| Albert Seymour | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 66,501 | 66,501 | - | - | Employee stock option | |
| Cameron Wheeler | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2018 | 31,160 | 31,160 | - | - | Employee stock option |